Zacks Investment Research has recently initiated coverage of RYTHM, Inc. (RYM) , assigning the stock an “Underperform” rating. The recommendation reflects serious concerns over the company’s financial health, operational sustainability and legal exposure, even as it seeks growth in the rapidly evolving cannabis and hemp wellness space.RYTHM enters the public market with a debt-heavy capital structure and limited cash runway. As of the end of the third quarter of 2025, the company carried $90.6 million in de ...

TORONTO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- TerrAscend Corp. (“TerrAscend” or the “Company”) (TSX: TSND) (OTCQX: TSNDF), a leading North American cannabis company, today announced an exclusive licensing agreement with Tyson 2.0, the cannabis brand founded by Mike Tyson, to launch its products across Maryland and Pennsylvania. "Cannabis changed my life, and I want to share that with the world,” said Mike Tyson, co-founder of Tyson 2.0. “Partnering with TerrAscend lets us reach more people and deliver products ...

Company’s first dispensary in the Garden State and 8th state where the Company operatesOpened to the public on November 7, 2025Grand opening celebration with exclusive promotions expected November 21, 2025 A Media Snippet accompanying this announcement is available by clicking on this link. BOCA RATON, Fla., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH) (OTCQX: JUSHF), a vertically integrated, multi-state cannabis operator, today announced the opening of its B ...

Industry Overview - The cannabis industry is evolving with potential U.S. federal reform and international market expansion, leading to increased global demand for both medical and recreational cannabis [1] - Analysts project the U.S. cannabis market could exceed $50 billion by 2030, driven by growing legalization efforts and shifting consumer attitudes [1] - Navigating this sector requires careful attention to fundamentals, technical analysis, and disciplined risk management [1] Company Highlights IM Cannabis Corp. (IMCC) - IM Cannabis is an international medical cannabis company headquartered in Israel, focusing on the medical market through pharmacy networks and online distribution [3][5] - The company reported a notable increase in annual revenue in 2024, reflecting rising medical demand in Israel and Germany, with modest revenue growth and a small net profit in Q1 2025 [5][11] - IM Cannabis represents a stable, lower-risk option for investors seeking medical cannabis exposure with a strong international foundation [5] Cronos Group Inc. (CRON) - Cronos Group is a Canadian cannabinoid company with a global strategy, focusing on both recreational and medical markets [6][8] - The company reported solid year-over-year revenue growth, supported by strong Canadian adult-use sales and expanding global demand, with improved gross profit margins [8] - Cronos maintains one of the strongest balance sheets in the cannabis industry, providing flexibility for future acquisitions or U.S. market entry [8][11] Aurora Cannabis Inc. (ACB) - Aurora Cannabis is one of Canada's largest cannabis producers, serving both recreational and medical markets with a wide international footprint [9][10] - The company reported significant revenue growth year-over-year, driven by rising medical sales and improved distribution efficiency, with a return to consistent profitability [10][11] - Aurora remains one of the few large-scale producers generating sustainable profits in the global cannabis space, appealing to investors looking for scale and stability [10][11]

Decibel Cannabis Company Conference Call Summary Company Overview - Decibel Cannabis Company is a Canadian cannabis company, established in 2019, and is the sixth largest by market share in Canada [1] - The company operates nationwide with brands including Qwest, Vox, and General Admission, the latter being a top-three brand in Canada [1] - The cannabis industry is experiencing significant growth, projected at a 25% compound annual growth rate (CAGR) through 2033 [1] Industry Insights - The cannabis market is highly fragmented with no single dominant player, allowing for growth opportunities alongside competitors [2] - Canada has contributed to a 54% growth in the global cannabis market through exports [2] - The Canadian market is viewed as mature, growing at approximately 5% annually, while nascent markets in Europe, particularly Germany, are experiencing rapid growth [4][5] International Expansion - Decibel has entered international markets, leveraging learnings from the Canadian market to drive growth [3] - The company expects double-digit growth from international sales, which currently represent 15% of total sales, compared to single-digit growth from domestic sales [7] - International sales increased by 187% quarter-over-quarter [7] - The company is well-positioned with necessary licensing for flower and extract exports, holding one of 13 licenses for flower exports and one of three for extract exports [13] Product Strategy - Decibel focuses on value-added products such as pre-rolls and vapes, which are differentiated from traditional flower products [8] - The company has a broad product array addressing 98% of total sales in the marketplace [9] - International markets are primarily medical, with a focus on flower products, but Decibel plans to introduce extract products as markets mature [9] Financial Performance - The company has maintained profitability and revenue growth, with a target of $25 million EBITDA for 2025 [13] - Year-over-year growth of 7% in the domestic market has been observed, with expectations of continued growth [15] - The company has generated adjusted free cash flow for the past three years and maintains margins close to 50% [16][17] Market Positioning - Decibel's management team has been consistent since inception, contributing to a strong track record of profitability in a challenging sector [6] - The company aims to balance debt and equity, maintaining a comfortable debt-to-EBITDA ratio of approximately two times [18] - The management believes that driving fundamental success through cash flow is key to creating long-term value for shareholders [17] Regulatory Environment - The cannabis industry is highly regulated, treated similarly to pharmaceuticals, which presents both challenges and opportunities for compliance and market entry [13] - Decibel's acquisition of a facility with a 110,000 square foot footprint allows for scalable growth with minimal capital expenditure [33] Future Outlook - The company anticipates further growth as more international markets legalize cannabis, with a focus on facilitating exports and leveraging existing capacities [19][30] - Decibel is positioned to capture market share as new countries come online, particularly in the EU [5][30] Conclusion - Decibel Cannabis Company has a proven track record in Canada and is strategically positioned for international growth, leveraging its experience and regulatory compliance to capitalize on emerging markets [19][34]

Core Insights - The marijuana sector is currently experiencing a long downtrend, but there is optimism for future growth as companies show profitability and success [2][3] - Identifying and investing in progressive and profitable marijuana companies can yield better returns, especially during market recoveries [3] Company Summaries - **TerrAscend Corp.**: Engages in the cultivation, production, and sale of cannabis products in Canada and the U.S., offering a variety of products including vaporizables, concentrates, topicals, flowers, tinctures, and edibles [4] - **Trulieve Cannabis Corp.**: Operates as a cannabis retailer, involved in the cultivation, processing, and manufacturing of cannabis products, distributing them through dispensaries and home delivery [7] - **Glass House Brands Inc.**: Functions as an integrated cannabis company in the U.S., with operations in retail, wholesale biomass, and cannabis-related consumer packaged goods [8]

Core Insights - Tilray Brands (NASDAQ: TLRY) has experienced a significant stock price increase of nearly 200%, rising from $0.42 in early July to $1.24, primarily due to potential reclassification of cannabis by the Trump administration from Schedule I to Schedule III [2][15] - The company is focusing on product differentiation and expanding its operations in Europe, including launching new EU-GMP certified medical cannabis strains in Germany [3] - Investors are questioning whether TLRY stock remains a compelling investment at its current price, with significant upside potential linked to the prospective reclassification of marijuana [4][16] Financial Performance - Tilray's revenues have grown at an average rate of 9.9% over the last three years, with a 4.1% increase from $789 million to $821 million in the past 12 months [12] - The latest quarterly revenues decreased by 2.3% to $225 million from $230 million a year prior [12] - The company reported an operating income of -$108 million, resulting in an operating margin of -13.1% and a cash flow margin of -11.5%, generating nearly -$95 million in operating cash flow [12] - TLRY's net income for the corresponding period was approximately -$2.2 billion, indicating a net margin of around -266.3% [12] Debt and Financial Stability - TLRY's debt stood at $329 million at the end of the most recent quarter, with a current market cap of $1.2 billion, resulting in a debt-to-equity ratio of 26.7% [13] - The company's cash (including cash equivalents) constitutes $256 million of $2.1 billion in total assets, leading to a cash-to-assets ratio of 12.4% [13] Stock Performance - TLRY stock has plummeted 97.6% from a peak of $63.91 on February 10, 2021, to $1.52 on June 23, 2023, compared to a peak-to-trough decline of 25.4% for the S&P 500 [14] - The stock has not yet rebounded to its pre-crisis peak, with the highest value since then being $3.31 on September 11, 2023, and currently trading at $1.24 [14] - TLRY stock dropped 88.4% from a high of $21.36 on January 15, 2020, to $2.47 on March 18, 2020, versus a peak-to-trough decline of 33.9% for the S&P 500 [14] Market Position and Strategy - Tilray Brands engages in the research, cultivation, production, marketing, and distribution of medical cannabis products across various segments, including GMP-certified flowers, oils, vapes, edibles, and topicals [7] - The company is enhancing its business operations by concentrating on product differentiation and developing new products for its premium segment [3]

Company Overview - Vireo Growth Inc. has commenced the sale of adult-use cannabis at all eight Green Goods® dispensaries in Minnesota as of September 16, 2025 [1][2] - The company has been operating in Minnesota's medical cannabis market since 2014, serving tens of thousands of patients [2][4] - Vireo aims to expand access, improve product quality, and support the transition to a sustainable adult-use market in Minnesota [2][4] Market Impact - The launch of the adult-use cannabis market in Minnesota, with a population of 5.7 million, is expected to drive strong organic revenue growth for Vireo [1][2] - Vireo is one of the state's licensed adult-use cannabis cultivators and retailers, positioning itself to benefit from the new market dynamics [2][4] Product Offering - Green Goods® dispensaries offer a comprehensive range of medical and adult-use cannabis products, including flower, pre-rolls, edibles, and beverages [3][4] - The dispensaries are strategically located in key areas such as Minneapolis, Blaine, Bloomington, Burnsville, Duluth, Moorhead, Rochester, and Woodbury [3] Leadership Commentary - Amber Shimpa, President of Vireo, expressed pride in making products available to all Minnesotans while maintaining commitment to medical patients [3] - Alexandra Breant, Head of Market in Minnesota, highlighted the significance of this milestone in expanding access and building community [3]

Core Viewpoint - Canopy Growth Corporation has launched a new at-the-market equity program to raise up to $200 million in common shares, aimed at supporting strategic investments and working capital [1][2]. Group 1: Equity Program Details - The new equity program allows for the issuance and sale of up to $200 million in common shares across U.S. and Canadian markets, with Canadian sales capped at $50 million [2]. - The program is governed by an equity distribution agreement dated August 29, 2025, with BMO Nesbitt Burns Inc. and BMO Capital Markets Corp. as agents [3]. - The program will remain active until June 5, 2027, or until the full $200 million is raised, with the Canadian portion ending earlier on July 5, 2026, or upon reaching its $50 million cap [3]. Group 2: Company Overview - Canopy Growth Corporation operates in the cannabis industry, producing and selling cannabis, hemp, and related products across Canada, Germany, and Australia [4]. - The company operates through four segments, including Canada Cannabis and International Markets, offering a variety of products such as dried flower, pre-rolls, edibles, vapes, oils, and concentrates [4]. - Canopy Growth markets its products under multiple brands, including Tweed, 7ACRES, Spectrum Therapeutics, Storz & Bickel, Wana, and DOJA [4].

Core Insights - Canadian cannabis firms with U.S. exposure are gaining attention due to their ability to bridge both markets, which positions them advantageously as U.S. policy shifts may provide new momentum for growth [1][2][24] - The U.S. legal cannabis market is projected to grow from approximately $37 billion in 2024 to over $91 billion by 2033, indicating a strong annual growth rate of more than 10 percent [2][24] - Recent headlines regarding potential federal reclassification of marijuana have fueled optimism, leading to a rally in cannabis stocks as traders seek follow-through momentum [3][24] Company Summaries Tilray - Tilray is one of the largest cannabis companies globally, focusing on cannabis-adjacent consumer goods in the U.S., with its beverage division being a key growth driver [5][6] - The company reported annual revenue exceeding $820 million, but also a significant net loss of over $2 billion, highlighting the need for tighter cost control despite strong performance in certain divisions [9][11] - The beverage segment achieved gross margins of around 40 percent, indicating strong consumer demand and pricing power [10] Village Farms International - Village Farms operates large-scale greenhouses, supplying cannabis in both Canada and the U.S., with a focus on efficient production rather than retail [12][14] - The company emphasizes wholesale supply to licensed retailers, which reduces capital costs and lowers risk while controlling significant production volumes [12][14] - Recent financial results show steady progress, with Canadian cannabis sales increasing year over year, benefiting from rising demand and improving margins [15][16] Canopy Growth - Canopy Growth is known for its broad product portfolio, including flower, pre-rolls, edibles, and wellness products, and has a presence in the U.S. through licensing and partnerships [17][20] - The company reported strong growth in Canadian medical cannabis sales, reaching $77 million, while international sales showed slight declines [21][22] - Canopy's gross margins expanded by 300 basis points year over year, and it reduced total debt by nearly 50 percent, indicating progress in strengthening its balance sheet [21][22] Market Outlook - The U.S. cannabis market's expansion presents significant opportunities for Canadian firms with U.S. exposure, particularly as potential rescheduling of marijuana could reduce restrictions and enhance valuations [2][24] - Volatility in the sector remains high, making technical analysis and risk management essential for investors looking to participate in the growth story [4][25]